A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults

Trial Profile

A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs UB 421 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors United BioPharma
  • Most Recent Events

    • 17 Nov 2017 According to an United BioPharma media release, the company has planned to implement the clinical trial in Taiwan, China and Thailand. Currently, it has been approved by Taiwan's Ministry of Health, and completed applications in China and Thailand.
    • 24 Oct 2017 Planned initiation date changed from 1 Jan 2018 to 1 Sep 2018.
    • 09 May 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top